Abstract
Twenty-eight acyl hydrazides (1-28) are subjected for nitric oxide scavenging activities and their structureactivity relationship (SAR) is established. Compounds 1-28 showed a varying degree of activity having IC50 values in the range of 9.1 ± 6.5 - 231.1 μM. It was found that twenty-five (25) out of twenty-eight (28) compounds, showed an excellent nitric oxide scavenging activity. It was observed that the activity mainly depends on the substitution on acyl hyrazide moiety. 3-Propylpyrozole-5-carbohydrazide (27) was found to be the most active in the series with an IC50 value of 9.1 μM. Thus, compound 27 may serve as a lead compound for further development as potent antioxidant agent.
Keywords: Acyl hydrazides, Free radicals, Reactive oxygen species (ROS), Nitric oxides scavengers, Antioxidant, Lead molecules, peroxynitrite, tonic relaxation, antitumor, antiglycation, antituberculosis, Nitroprusside sodium, heterocyclic, radical-scavenging, antimicrobial, conventional synthetic methods
Letters in Drug Design & Discovery
Title: Acyl Hydrazides: Potent Antioxidants
Volume: 9 Issue: 2
Author(s): Khalid Mohammed Khan, Mubeen Rani, Nida Ambreen, Asma Ejaz, Shahnaz Perveen, Syed Moazzam Haider, Mohammad Iqbal Choudhary and Wolfgang Voelter
Affiliation:
Keywords: Acyl hydrazides, Free radicals, Reactive oxygen species (ROS), Nitric oxides scavengers, Antioxidant, Lead molecules, peroxynitrite, tonic relaxation, antitumor, antiglycation, antituberculosis, Nitroprusside sodium, heterocyclic, radical-scavenging, antimicrobial, conventional synthetic methods
Abstract: Twenty-eight acyl hydrazides (1-28) are subjected for nitric oxide scavenging activities and their structureactivity relationship (SAR) is established. Compounds 1-28 showed a varying degree of activity having IC50 values in the range of 9.1 ± 6.5 - 231.1 μM. It was found that twenty-five (25) out of twenty-eight (28) compounds, showed an excellent nitric oxide scavenging activity. It was observed that the activity mainly depends on the substitution on acyl hyrazide moiety. 3-Propylpyrozole-5-carbohydrazide (27) was found to be the most active in the series with an IC50 value of 9.1 μM. Thus, compound 27 may serve as a lead compound for further development as potent antioxidant agent.
Export Options
About this article
Cite this article as:
Mohammed Khan Khalid, Rani Mubeen, Ambreen Nida, Ejaz Asma, Perveen Shahnaz, Moazzam Haider Syed, Iqbal Choudhary Mohammad and Voelter Wolfgang, Acyl Hydrazides: Potent Antioxidants, Letters in Drug Design & Discovery 2012; 9 (2) . https://dx.doi.org/10.2174/157018012799079798
DOI https://dx.doi.org/10.2174/157018012799079798 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Incidence and Prevention of Thromboembolic Events in One Stage Bilateral Total Hip Arthroplasty: A Systematic Review
Current Vascular Pharmacology Editorial [Hot Topic: Stroke Prevention (Guest Editors: T. Tatlisumak, K. Rantanen and M. Fisher)]
Current Drug Targets Prevention of Ischemic Stroke: Surgery
Current Drug Targets Editorial [Hot Topic: Ischemic Stroke in Very Old Patients (Guest Editor: Maria Cristina Zurru)]
Cardiovascular & Hematological Disorders-Drug Targets Recent Developments on Coronary Microvasculopathy after Heart Transplantation:A New Target in the Therapy of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology The Genetic Regulation of ADPRT/PARP-1 in Aging and Cancer Susceptibility
Current Pharmacogenomics Vitamins in Heart Failure: Friend or Enemy?
Current Pharmaceutical Design Endothelin Receptor Antagonists - An Overview
Current Medicinal Chemistry Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders
Current Medicinal Chemistry Expressions of eNOS3 and Ve-Cadherin in Microvascular Endothelium at 7-Day of Reperfused Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Biological Responses to Hydrogen Molecule and its Preventive Effects on Inflammatory Diseases
Current Pharmaceutical Design Blood Brain Barrier in Hypoxic-Ischemic Conditions
Current Neurovascular Research Lignans' Potential in Pre and Post-onset Type 2 Diabetes Management
Current Diabetes Reviews Carbon Monoxide and Iron Modulate Plasmatic Coagulation in Alzheimer’s disease
Current Neurovascular Research Conformational Changes Preceding Amyloid-Fibril Formation of Amyloid- Beta, Prion Protein and Stefin B; Parallels in pH Dependence
Medicinal Chemistry Reviews - Online (Discontinued) subject Index To Volume 1
Current Drug Targets - CNS & Neurological Disorders von Willebrand Factor, von Willebrand Factor-Cleaving Protease, and Shear Stress
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of Heme Oxygenases in Cardiovascular Syndromes and Co-morbidities
Current Pharmaceutical Design GRK2 Inhibition in Heart Failure: Something Old, Something New
Current Pharmaceutical Design Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets